Ocumension Therapeutics (HKSE:01477) EV-to-EBIT : -9.08 (As of Jun. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ocumension Therapeutics's Enterprise Value is HK$3,757.0 Mil. Ocumension Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-413.6 Mil. Therefore, Ocumension Therapeutics's EV-to-EBIT for today is -9.08.

The historical rank and industry rank for Ocumension Therapeutics's EV-to-EBIT or its related term are showing as below:

HKSE:01477' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.69 Med: -7.92 Max: -0.86
Current: -9.08

During the past 6 years, the highest EV-to-EBIT of Ocumension Therapeutics was -0.86. The lowest was -26.69. And the median was -7.92.

HKSE:01477's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs HKSE:01477: -9.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ocumension Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was HK$3,618.2 Mil. Ocumension Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-413.6 Mil. Ocumension Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -11.43%.

Ocumension Therapeutics EV-to-EBIT Historical Data

The historical data trend for Ocumension Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics EV-to-EBIT Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-5.02

-29.97

-11.97

-8.75

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial						-29.97	-	-11.97	-	-8.75

Competitive Comparison of Ocumension Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Ocumension Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocumension Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's EV-to-EBIT falls into.

Ocumension Therapeutics EV-to-EBIT Calculation

Ocumension Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3756.985	/	-413.618
	=	-9.08

Ocumension Therapeutics's current Enterprise Value is HK$3,757.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-413.6 Mil.

Ocumension Therapeutics (HKSE:01477) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ocumension Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-413.618	/	3618.23972
	=	-11.43 %

Ocumension Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was HK$3,618.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-413.6 Mil.

Ocumension Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Liu Ye	2101 Beneficial owner
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Chen Ziqing	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Boyu Capital Fund Iv, L.p	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines